Cailin Conner

DocwireNews

Major depression disorder (MDD), a common mental health disorder that affects up to three million people in the US each year, can be treated with transcranial magnetic stimulation (TMS). TMS is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to relieve symptoms of depression. The effects of TMS protocols for MDD are thought to depend on synaptic plasticity. Synaptic plasticity, change that occurs at the junctions between neurons, controls how effectively two neurons communicate with each other. According to the <a href="https://qbi.uq.edu.au/brain-basics/brain/brain-physiology/what-synaptic-plasticity#:~:text=What%20is%20the%20function%20of,the%20volume%20of%20a%20conversation.">Queensland Brain Institute</a>, &ldquo;The strength of the communication between two synapses can be likened to the volume of a conversation.&rdquo; Theta-burst stimulation (TBS) protocol synaptic plasticity, a form of patterned TMS, is known to be N-methyl-D-aspartate (NMDA)&ndash;receptor dependent; however, research on whether enhancing NMDA-receptor signaling can improve outcomes in the treatment of MDD is lacking.Published in <a href="https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2796973">JAMA Psychiatry</a>, researchers from the Mathison Centre for Mental Health Research and Education and Hotchkiss Brain Institute at the University of Calgary conducted a double-blind, placebo-controlled, randomized clinical trial to investigate whether low doses of the NMDA-receptor partial-agonist, D-cycloserine, would enhance intermittent TBS (iTBS) treatment outcomes in MDD. To meet the inclusion criteria, the MDD patients needed to have had a major depressive episode with a score of &gt;18 on the 17-item Hamilton Depression Rating Scale, a Young Mania Rating Scale score of &lt;8, and normal blood work. In total, 50 patients were enrolled in the study. The patients were assigned to either iTBS plus placebo or iTBS plus D-cycloserine for the first two weeks followed by just iTBS for the remaining two weeks. The primary outcomes for this study included change in depressive symptoms, measured using the Montgomery-&Aring;sberg Depression Rating Scale (MADRS) at the end of treatment. Researchers also investigated clinical response, clinical remission, and Clinical Global Impression (CGI) scores.Patients in the iTBS plus D-cycloserine group had an improvement of -6.15 in MARDS scores, compared with an improvement of -2.43 in the iTBS plus placebo group. Additionally, patients in the iTBS plus D-cycloserine group had higher rates of clinical response to treatment than those in the placebo group (73.9 percent and 29.3 percent, respectively. iTBS plus D-cycloserine patients had a mean rate of clinical remission of 39.1 percent versus just 4.2 percent in patients who received iTBS plus placebo. Researchers reported that no serious adverse events occurred in either group. According to researchers, &ldquo;Findings from this clinical trial indicate that adjunctive D-cycloserine may be a promising strategy for enhancing transcranial magnetic stimulation treatment outcomes in MDD using iTBS requiring further investigation.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Treating Major Depressive Disorder With D-Cycloserine Plus Theta-Burst Stimulation

Depression

Major depression disorder (MDD), a common mental health disorder that affects up to three million people in the US each year, can be treated with transcranial magnetic ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe